Search Results
ASH 2020 | Prof. Eunice Wang: Recent advances in the treatment of AML
Searching for Effective Treatment in Newly Diagnosed FLT3 Positive AML | Eunice Wang | ASH 2021 #AML
Eunice Wang, MD, on how minimal residual disease is being integrated into treatment decisions in AML
Eunice Wang, MD, on strategies for frail AML patients who do not qualify for intensive therapy
Treatment Landscape for Acute Myeloid Leukemia Appears Hopeful for Patients
Eunice Wang, MD, shares exciting data for acute myeloid leukemia (AML) presented at ASH 2017
Novel treatment paradigms for AML at ASH 2021
Updates in the Treatment Landscape of AML
Prof. Eunice Wang | ASH 2017 | Crenolanib and SC in young newly diagnosed FLT3 mutated AML
Eunice Wang, MD, on the importance of drug potency in the treatment of FLT3-ITD positive AML
Eunice S. Wang, MD, on immunotherapy and its potential role in treating hematological malignancies
Eunice Wang, MD, on incorporating Vyxeos (liposomal daunorubicin and cytarabine) in AML treatment
